By Ahmed Aboulenein WASHINGTON, Dec 18 (Reuters) - Americans enrolled in Medicare will pay about 50% less out of pocket in ...
Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.
Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer Ingelheim has informed the Company ...
Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...
Nxera Pharma, which recently announced a number of job cuts in Cambridge, is putting on a brave face after suffering another ...
Pharma marketers enter 2026 asking where DTC fits in the DTP era. | Pharma marketers enter 2026 asking where DTC fits in the ...
AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon to announce agreements ...
E-cigarettes, nicotine pouches, and heated tobacco hurt blood vessels, increase heart disease risk. All nicotine products ...
Informing patients about bariatric surgery is a comprehensive discussion, so aim to provide the most up-to-date information about both pre- and post-surgery expectations.
The perception of GLP-1s — and the people who use them — is getting better, but work still must be done to avoid stigma.
A generic product for managing pain and inflammation associated with osteoarthritis (OA) in canines has been approved by FDA ...
TipRanks on MSN
Nxera Pharma Regains Full Rights to Phase 2–Ready Schizophrenia Drug After Boehringer Ingelheim Opts Out
Sosei Group ( ($JP:4565) ) has provided an announcement. Nxera Pharma will regain full rights to its GPR52 agonist program for schizophrenia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results